KEYNOTE-867

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

Screened window

Apr 23, 2019 → Oct 30, 2026

Cited window

Apr 23, 2020 → Oct 30, 2026

Retrieved

Oct 31, 2026

Title

A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Unresected Stages I or II Non Small Cell Lung Cancer (NSCLC) (KEYNOTE-867)

Registry

NCT03924869

Study IDs

3475-867 · MK-3475-867 (MSD) · KEYNOTE-867 (MSD) · 194909 (JAPAC-CTI) · 2022-500413-11-00 (EU CT) · U1111-1275-8515 (UTN) · 2018-004320-11

Sponsor

Merck Sharp & Dohme LLC

Design

Phase 3 · Interventional, randomized, parallel

Status

Terminated

Enrollment

448 actual

Registered

2019-04-23

Start

2019-06-25 actual

Primary completion

2024-06-11 actual

Primary endpoint

Event-free Survival (EFS)

Interventions

3 registered

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

• –Discussion that does not name the trial may be missing from this edition.
• –Not yet captured in this edition: a remark on studying upfront alternatives to surgery to optimize cure in stage I lung cancer.
• –Not yet captured in this edition: a view on uncertainty over adjuvant versus salvage immunotherapy and similar trial designs in unresected early-stage lung cancer.
• –Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
• –116 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
• –Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing.
• –The report describes the sources reviewed for this edition, not all public discussion or the frequency of opinions among HCPs. Trial-name-focused source selection may miss unnamed references and transcription variants.
• –Some potentially relevant passages were not fully assessed. Portions of the salvage-control, treatment-duration and financial-burden discussion may contain additional reasons or qualifications not represented here.
• –The account of the local-treatment dissemination exchange is incomplete, including an additional response to physiological counterarguments and uncertainty in a relayed radiation caution's attribution. A complete account of treatment choices when surgery could not proceed after neoadjuvant therapy is also unavailable.
• –Many numerical results, subgroup observations and proposed explanations are reported by speakers. Detailed event adjudication, subgroup tables and full safety analyses are not available in the statements used here; these views cannot establish misclassification, a predictive subgroup or a causal mechanism.
• –The primary publication passage provides a conclusion, while the protocol amendment provides an interim stopping account and revised follow-up plans. Neither justifies treating every social-post numerical or mechanistic interpretation as a primary result.
• –Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
• –Source descriptions of a speaker as presenting KEYNOTE-867 and another speaker as involved in KEYNOTE-867 are attributed descriptions of involvement, not evidence that their views are independent external assessments.
• –Historical statements about eligibility, treatment schedules, enrollment targets and site access are preserved as dated accounts. Differences between those accounts are not silently reconciled, and post dates do not establish meeting dates or changes of mind.
• –Comparisons with I-SABR, S1914, surgical studies and other radiation–immunotherapy experiences involve different regimens, populations or endpoints. They explain speakers' reasoning but do not establish comparative efficacy between those alternatives.

How reports are built and checked: Methods.

Last checked for new commentary Oct 31, 2026. A new or changed finding gets a new version number; added evidence alone is a smaller update. No corrections.

Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.

Help me decide whether to buy the Erudio report "KEYNOTE-867" (NCT03924869), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.

1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "keynote-867-03924869". If you cannot make requests, read https://www.erudio.com/reports/keynote-867-nct03924869.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email and the product: the current edition, or 3, 6 or 12 months of weekly updates. Call create_order with report "NCT03924869", that product and email, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id erudio-nct03924869 and sections ["all"], and summarize the findings for me with their sources. The full report is large (about 500 KB): save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.

When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.

curl https://www.erudio.com/reports/keynote-867-nct03924869.json
curl https://www.erudio.com/reports/keynote-867-nct03924869.md

# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "keynote-867-03924869" })